Elicio Therapeutics Reports Post-Hoc Phase 2 AMPLIFY-7P Study; Stock Down Over 70%

Elicio Therapeutics reported Phase 2 AMPLIFY-7P results that missed the primary endpoint in the overall population, though post-hoc analyses suggested potential benefit in certain patients with resected mKRAS. The readout is mixed but leans negative because the main trial objective was not achieved. The news is likely to affect ELTX sentiment more than the broader biotech sector.

Analysis

Elicio Therapeutics reported Phase 2 AMPLIFY-7P results that missed the primary endpoint in the overall population, though post-hoc analyses suggested potential benefit in certain patients with resected mKRAS. The readout is mixed but leans negative because the main trial objective was not achieved. The news is likely to affect ELTX sentiment more than the broader biotech sector.